Cell-free DNA technology can help screen for HDFN in infants
Fetal genotyping with the use of cell-free DNA technology can assist in screening for red blood cell fetal antigens linked to HDFN.
Fetal genotyping with the use of cell-free DNA technology can assist in screening for red blood cell fetal antigens linked to HDFN.
In a recent study, non-invasive prenatal testing was able to help researchers diagnose fetal anemia earlier during pregnancy.
Researchers are studying a new approach to HDFN prevention to reduce cases in countries where incidence rates remain high.
A recent analysis showed there is much variation in postnatal HDFN treatment and outcomes across the world.
A recent study showed limited data exist on the risks associated with anti-G during pregnancy, including the development of HDFN.
A recent review showed Rhesus D (RhD)-negative red blood cell (RBC) products should be the first choice for women who require resuscitation.
A case report described an infant with concurrent HDFN and SMA who was succesfully treated with an onasemnogene abeparvovec infusion.
A recent study found certain groups of white blood cells may be linked to several adverse outcomes for neonates.
A recent study showed exchange transfusion treatment is effective in lowering the bilirubin levels of newborns diagnosed with HDFN.
A recent study showed administering certain types of blood to RhD-negative patients could help conserve blood supplies during a shortage.